《儿童结核分枝杆菌潜伏感染检测和预防性治疗》标准解读

doi:10.19982/j.issn.1000-6621.20220426

中国防痨杂志 ›› 2023, Vol. 45 ›› Issue (1): 13-17.doi: 10.19982/j.issn.1000-6621.20220426

《儿童结核分枝杆菌潜伏感染检测和预防性治疗》标准解读

王泽明¹, 申阿东²^,³()

¹首都医科大学附属北京友谊医院儿科,北京 100050
²国家儿童医学中心/首都医科大学附属北京儿童医院/北京市儿科研究所/儿科学国家重点学科/国家呼吸系统疾病临床医学研究中心/儿科重大疾病研究教育部重点实验室/儿童呼吸道感染性疾病研究北京市重点实验室,北京 100045
³郑州大学附属儿童医院/河南省儿童医院/郑州儿童医院,郑州 451161

收稿日期:2022-11-11 出版日期:2023-01-10 发布日期:2022-12-30
通信作者: 申阿东 E-mail:shenadong@bch.com.cn

Interpretation of the standard of Detection and preventive treatment of latent tuberculosis infection in children

Wang Zeming¹, Shen Adong²^,³()

¹Department of Pediatrics, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
²Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
³Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou 451161, China

Received:2022-11-11 Online:2023-01-10 Published:2022-12-30
Contact: Shen Adong E-mail:shenadong@bch.com.cn

摘要/Abstract

摘要：

2021年7月9日中国防痨协会发布《T/CHATA 015-2021儿童结核分枝杆菌潜伏感染检测和预防性治疗》标准。笔者现就该标准从结核分枝杆菌潜伏感染筛查人群、筛查方法、诊断标准及抗结核预防性治疗等方面进行解读,旨在进一步提高临床儿科医师及结核病诊疗人员对儿童结核分枝杆菌潜伏感染的认识,规范儿童结核分枝杆菌潜伏感染的管理。

关键词: 儿童, 分枝杆菌,结核, 感染, 诊断, 预防和防护用药

Abstract:

The standard of Detection and preventive treatment of latent tuberculosis infection in children (T/CHATA 015-2021) was published by the Chinese Antituberculosis Association on July 9, 2021. This standard was interpreted from the aspects of screening population, screening methods, diagnostic standards and anti-tuberculosis preventive treatment of latent tuberculosis infection, aiming to further improve the cognition of clinical pediatricians and staff related to tuberculosis diagnosis and treatment on latent tuberculosis infection in children, and standardize the management of latent tuberculosis infection in children.

Key words: Child, Mycobacterium tuberculosis, Infection, Diagnosis, Protective agents

中图分类号:

R52
R725

王泽明, 申阿东. 《儿童结核分枝杆菌潜伏感染检测和预防性治疗》标准解读[J]. 中国防痨杂志, 2023, 45(1): 13-17. doi: 10.19982/j.issn.1000-6621.20220426

Wang Zeming, Shen Adong. Interpretation of the standard of Detection and preventive treatment of latent tuberculosis infection in children[J]. Chinese Journal of Antituberculosis, 2023, 45(1): 13-17. doi: 10.19982/j.issn.1000-6621.20220426

参考文献 21

[1]	Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016, 13(10): e1002152. doi:10.1371/journal.pmed.1002152. doi: 10.1371/journal.pmed.1002152. URL
[2]	World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
[3]	Shah M, Dorman SE. Latent Tuberculosis Infection. N Engl J Med, 2021, 385(24): 2271-2280. doi:10.1056/NEJMcp2108501. doi: 10.1056/NEJMcp2108501. URL
[4]	Martinez L, Shen Y, Mupere E, et al. Transmission of Mycobacterium Tuberculosis in Households and the Community: A Systematic Review and Meta-Analysis. Am J Epidemiol, 2017, 185(12): 1327-1339. doi:10.1093/aje/kwx025. doi: 10.1093/aje/kwx025. URL
[5]	阮巧玲, 黄希田, 刘雪峰, 等. 免疫受损人群的潜伏性结核感染筛查和预防性治疗. 中国防痨杂志, 2017, 39(7): 765-769. doi:10.3969/j.issn.1000-6621.2017.07.020. doi: 10.3969/j.issn.1000-6621.2017.07.020.
[6]	Xie X, Li F, Chen JW, et al. Risk of tuberculosis infection in anti-TNF-α biological therapy: from bench to bedside. J Microbiol Immunol Infect, 2014, 47(4): 268-274. doi:10.1016/j.jmii.2013.03.005. doi: 10.1016/j.jmii.2013.03.005 pmid: 23727394
[7]	Carranza C, Pedraza-Sanchez S, de Oyarzabal-Mendez ED, et al. Diagnosis for Latent Tuberculosis Infection: New Alternatives. Front Immunol, 2020, 11: 2006. doi:10.3389/fimmu.2020.02006. doi: 10.3389/fimmu.2020.02006 pmid: 33013856
[8]	Youssef J, Novosad SA, Winthrop KL. Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am, 2016, 42(1): 157-176, ix-x. doi:10.1016/j.rdc.2015.08.004. doi: 10.1016/j.rdc.2015.08.004. URL
[9]	Brock I, Weldingh K, Lillebaek T, et al. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med, 2004, 170(1): 65-69. doi:10.1164/rccm.200402-232OC. doi: 10.1164/rccm.200402-232OC. URL
[10]	Böncüogˇlu E, Kıymet E, Şahinkaya Ş, et al. Usefulness of screening tests for diagnosis of latent tuberculosis infection in children. Pediatr Pulmonol, 2021, 56(5): 1114-1120. doi:10.1002/ppul.25173. doi: 10.1002/ppul.25173. URL
[11]	Zenner D, Beer N, Harris RJ, et al. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. Ann Intern Med, 2017, 167(4): 248-255. doi:10.7326/M17-0609. doi: 10.7326/M17-0609 pmid: 28761946
[12]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 4: Treatment—Drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2020.
[13]	祁雪, 田建岭, 孙琳, 等. 儿童结核分枝杆菌潜伏感染的筛查和预防性治疗. 中国防痨杂志, 2018, 40(5): 447-454. doi:10.3969/j.issn.1000-6621.2018.05.003. doi: 10.3969/j.issn.1000-6621.2018.05.003.
[14]	Malik AA, Farooq S, Jaswal M, et al. Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health, 2021, 5(5): 350-356. doi:10.1016/s2352-4642(21)00052-3. doi: 10.1016/S2352-4642(21)00052-3 pmid: 33770510
[15]	Radtke KK, Hibma JE, Hesseling AC, et al. Pragmatic global dosing recommendations for the 3-month, once-weekly rifa-pentine and isoniazid preventive TB regimen in children. Eur Respir J, 2021, 57(1): 2001756. doi:10.1183/13993003.01756-2020. doi: 10.1183/13993003.01756-2020. URL
[16]	Yang H, Yang Y, Hu ZD, et al. High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection—A single center study. PLoS One, 2021, 16(6): e0253159. doi:10.1371/journal.pone.0253159. doi: 10.1371/journal.pone.0253159.
[17]	Ayieko J, Abuogi L, Simchowitz B, et al. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infect Dis, 2014, 14: 91. doi:10.1186/1471-2334-14-91. doi: 10.1186/1471-2334-14-91 pmid: 24555539
[18]	Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med, 2014, 161(6): 419-428. doi:10.7326/M14-1019. doi: 10.7326/M14-1019 pmid: 25111745
[19]	Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis, 2007, 45(6): 715-722. doi:10.1086/520983. doi: 10.1086/520983. pmid: 17712755
[20]	Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011, 365(23): 2155-2166. doi:10.1056/NEJMoa1104875. doi: 10.1056/NEJMoa1104875. URL
[21]	Villarino ME, Scott NA, Weis SE, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr, 2015, 169(3): 247-255. doi:10.1001/jamapediatrics.2014.3158. doi: 10.1001/jamapediatrics.2014.3158 pmid: 25580725

《儿童结核分枝杆菌潜伏感染检测和预防性治疗》标准解读

Interpretation of the standard of Detection and preventive treatment of latent tuberculosis infection in children

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	王前, 王嘉, 李玉红, 刘二勇, 周林. 重视儿童结核病防治关爱儿童健康[J]. 中国防痨杂志, 2023, 45(1): 1-5.
[2]	王泽明, 申阿东. 《儿童中枢神经系统结核的诊断》团体标准解读[J]. 中国防痨杂志, 2023, 45(1): 18-24.
[3]	李桂莲, 方敏, 姜靖伟, 王瑞欢, 钱程宇, 于晋杰, 曹滨, 许达, 赵秀芹, 李马超, 刘海灿, 孙琳, 朱渝, 万康林. 肺结核患儿胃液样本结核分枝杆菌培养阳性率提高方法的探讨[J]. 中国防痨杂志, 2023, 45(1): 31-37.
[4]	李翔, 付旭文, 许艳玲, 干玮, 杞敏, 黄瑛. CT征象联合外周血嗜酸性粒细胞对鉴别儿童胸肺型并殖吸虫病与结核性胸膜炎的价值研究[J]. 中国防痨杂志, 2023, 45(1): 38-44.
[5]	陈芳, 张小佛, 周海依, 张锋, 王曼知. 儿童抗结核药物性肝损伤状况及相关影响因素分析[J]. 中国防痨杂志, 2023, 45(1): 45-51.
[6]	樊丽超, 焦伟伟, 吴浩宇, 申阿东, 陈禹. 世界卫生组织《结核病整合指南模块5:儿童和青少年结核病管理》解读[J]. 中国防痨杂志, 2023, 45(1): 6-12.
[7]	邓国防, 王庆文. 重视风湿性疾病合并结核感染的多学科诊治[J]. 中国防痨杂志, 2022, 44(9): 865-868.
[8]	国家感染性疾病临床医学研究中心/深圳市第三人民医院, 北京大学深圳医院, 中国医学科学院北京协和医院, 中国防痨协会, 《中国防痨杂志》编辑委员会, 深圳市炎症与免疫性疾病重点实验室. 风湿性疾病患者合并结核分枝杆菌潜伏感染诊治的专家共识[J]. 中国防痨杂志, 2022, 44(9): 869-879.
[9]	王玉香, 陈秋奇, 余鑫鑫, 詹森林, 张培泽, 邓国防. 3HP方案治疗风湿性疾病合并结核分枝杆菌潜伏感染的前瞻性研究[J]. 中国防痨杂志, 2022, 44(9): 906-910.
[10]	魏赣辉, 张加成, 邱小伟. 容积CT值量化判断5mm以上肺结核病灶活动性的应用价值[J]. 中国防痨杂志, 2022, 44(9): 934-939.
[11]	吴文琪, 钟剑球, 何娟, 邓国防, 王庆文. 风湿性疾病患者结核分枝杆菌潜伏感染激活机制的研究进展[J]. 中国防痨杂志, 2022, 44(9): 954-959.
[12]	陈秋奇, 韩婷婷, 王庆文, 邓国防. 风湿性疾病合并结核分枝杆菌潜伏感染的诊治进展[J]. 中国防痨杂志, 2022, 44(9): 960-965.
[13]	成君, 高磊. 结核分枝杆菌感染检测在学校人群中的应用[J]. 中国防痨杂志, 2022, 44(8): 757-761.
[14]	成君, 陆伟. 《基层医疗卫生机构结核感染预防与控制指南》解读[J]. 中国防痨杂志, 2022, 44(8): 762-767.
[15]	卢鹏, 王荣, 刘家松, 刘巧, 丁晓艳, 陆伟, 竺丽梅. 结核菌素皮肤试验诊断结核分枝杆菌潜伏感染学校人群预防性服药临界值的确定[J]. 中国防痨杂志, 2022, 44(8): 797-801.